EquityBulls

Latest News

Tamilnadu Petroproducts Ltd receives TNPCB nod for expanded capacity of Linear Alkyl Benzene plant
S&P Upgrades IIFL Finance's Outlook to 'Positive' On Recovering Market Share in Gold Loans, 'B+/B' Ratings Affirmed
Trishakti Industries Ltd secures order from Afcons Infrastructure Ltd
Persistent and DigitalOcean announce strategic partnership to advance accessible, scalable and secure AI
ITCONS E-Solutions Ltd bags new contract

Keywords Selected: Biosimilar

Stock Report

Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide
Lupin and Valorum Enter into an Exclusive Licensing Agreement for Biosimilar Armlupeg™ in the United States
Lupin and Zentiva Sign License and Supply Agreement for Commercializing Certolizumab
Lupin Ltd enters into agreement with Zentiva for biosimilar Certolizumab Pegol
CuraTeQ Biologics receives positive opinion for biosimilar Dazublys® from EMA
Biocon Biologics secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
Biocon Biologics announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio
European Commission approves Biocon Biologics' Ustekinumab Biosimilar
U.S.FDA Approves Biocon Biologics' YESINTEK™, Bmab 1200 biosimilar to J&J's Stelara® (Ustekinumab)
Dr. Reddy's receives positive CHMP opinion from European Medicines Agency for its proposed Rituximab biosimilar
Zydus and Dr. Reddy's announce licensing agreement for co‐marketing of Pertuzumab biosimilar
EMA Approves Biocon Biologics' New mAbs Facility in India and Renews GMP Certifications for India and Malaysia Sites
Ipca Laboratories Ltd enters into technology transfer agreement with Omexa Formulary Pvt Ltd
CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product
Biocon Biologics Secures Canada Market Entry Date for YESAFILI®, a Proposed Biosimilar to EYLEA®
CuraTeQ Biologics receives recommendation for grant of marketing authorization of 'biosimilar trastuzumab' from SEC operating under the aegis of CDSCO
Glenmark is the first to launch Biosimilar of Popular Anti‐Diabetic Drug, Liraglutide, in India
Biocon Biologics Receives European Commission Approval for YESAFILI®, Biosimilar Aflibercept
Biocon Biologics announces Positive CHMP Opinion for YESAFILI®, Biosimilar Aflibercept
CuraTeQ obtains exclusive rights for BioFactura's Ustekinumab biosimilar
CuraTeQ Biologics announces positive result in phase 3 clinical trial for its proposed Trastuzumab Biosimilar product
Biocon Biologics' Hulio® Biosimilar to Humira®, now available in the United States
Dr. Reddy's successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe
Lupin receives Health Canada approval for Rymti®, biosimilar Etanercept